Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005203 | Clinical Therapeutics | 2005 | 9 Pages |
Abstract
Monotherapy with V160 was effective in these patients with stage 2 or 3 systolic hypertension. Significant additional reductions in SBP and DBP and an increase in responder rates were achieved with the addition to V160 of HCTZ12.5 and HCTZ25, with no significant effect on tolerability.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Lacourcière,, MSc Poirier,, PhD Hebert,, PhD Assouline,, PhD Stolt,, MSc Rehel,, MD Khder,,